



# **Borders Formulary Committee**

## **Annual Report**

**April 2020 – March 2021**

## CONTENTS

1	NHS Borders Formulary Committee Purpose	Page 3
2	BFC Membership	Page 3
3	Business	Page 3
4	BFC – Formulary Updates	Page 4
5	BFC – Applications and Decisions	Page 5-7
6	BFC Meeting Attendees 2020/21	Page 7

## **1. Purpose**

Borders Formulary Committee is a sub committee of the Area Drug and Therapeutics Committee and is accountable to the Strategy Group.

Its purpose is to provide NHS Borders Board with the assurance that mechanisms are in place and effective across NHS Borders to manage requests to support cost-effective, evidence based, prescribing of medicines.

## **2. BFC Membership**

During the financial year ending 31 March 2021, membership of NHS Borders Formulary Committee comprised:

Mrs Alison Wilson (Chair) – Director of Pharmacy

Ms Liz Leitch – Formulary Pharmacist

Mrs Cathryn Park - Lead Pharmacist Acute Care & Medicines Governance and Deputy Director of Pharmacy

Mr Keith Maclure – Prescribing Support Pharmacist

Dr Paul Neary – Consultant Cardiologist

Dr Nicola Henderson – GP

Amy Campbell – ST4 (representative for Junior Doctors) – until June 2020

Charlotte Squires – Registrar (representative for Junior Doctors) – from August 2020

Michael McDermott - Registrar (representative for Junior Doctors) – from August 2020

Fiona Grant – Consultant Physiotherapist – from December 2020

Minute Secretary

Kate Warner – PA to Director of Pharmacy

## **3 Business**

Core agenda items on the Committee's agenda include:-

- Committee members review New Medicine Applications for drugs from NHS Borders clinicians to be included in the formulary.
- Committee members note medicines reviewed by the Scottish Medicine Consortium (SMC), and guidance published by NICE, SIGN and NHS Quality Improvement Scotland (QIS).
- Borders Joint Formulary Updates – committee members review and approve changes to formulary sections. The committee supports development of guidelines & protocols relating to safe use of medicines.
- Patient Safety.
- For noting – minutes from Anticoagulation Committee, Tissue Viability Group, Wound Formulary Group, IV Therapy Group and NHS Lothian Formulary Committee; Single National Formulary and East Region Formulary updates.

## 4 BFC – Formulary, Guideline and Protocol Updates

<b>FORMULARY UPDATES BROUGHT TO BFC MEETING – 8<sup>TH</sup> APRIL 2020</b>
COVID PANDEMIC - MEETING CANCELLED
<b>GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 8<sup>TH</sup> APRIL 2020</b>
COVID PANDEMIC - MEETING CANCELLED
<b>FORMULARY UPDATES BROUGHT TO BFC MEETING – 10<sup>TH</sup> JUNE 2020</b>
Paediatrics – Sytron to Sodifer brand switch; switch from Nizatadine to Famotidine; update on Guanfacine. SMC Decisions update.
<b>GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 10<sup>TH</sup> JUNE 2020</b>
Management of Vitamin D insufficiency/deficiency; EAMS Remdesivir treatment of Covid19 Minute from Lothian Formulary Committee.
<b>FORMULARY UPDATES BROUGHT TO BFC MEETING – 19<sup>TH</sup> AUGUST 2020</b>
Update to Borders Abbreviated Formulary; Infections section on Genital Tract infections. SMC Decisions update and East Regional Formulary update.
<b>GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 19<sup>TH</sup> AUGUST 2020</b>
Pharmacy First Scotland service; Update to Electrolyte Deficiency Guidelines; Public Health Primary & Secondary Care Guidelines – lipid lowering guidelines; EAMS Nivolumab; Covid19 medicines. Minute from Lothian Formulary Committee.
<b>FORMULARY UPDATES BROUGHT TO BFC MEETING – 21<sup>ST</sup> OCTOBER 2020</b>
Budesonide (Budenofalk); Budenoside (Entocort); Enema – formulary replacements; Lower Limb Compression Formulary. SMC Decisions update and East Regional Formulary update.
<b>GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 21<sup>ST</sup> OCTOBER 2020</b>
Steroid Emergency Card; Non Formulary request form update; Guanfacine SCA Lothian; BFC Constitution – Terms of Reference update; Priadel; increased membership of BFC required. Minute from Anticoagulation Committee; IV Therapy Group; Lothian Formulary Committee.
<b>FORMULARY UPDATES BROUGHT TO BFC MEETING – 16<sup>TH</sup> DECEMBER 2020</b>
Update to Inflammatory Bowel Disease chapter; update to Eye chapter; Bevacizumab and wAMD discussion; Covid19 – Remdesivir; Covid Medicines website page; Freestyle Libre2 Sensor. SMC Decisions update and East Regional Formulary update.
<b>GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 16<sup>TH</sup> DECEMBER 2020</b>
Guidance for Rapid Reversal of Rivaroxaban and Apixaban with Andexanet alfa in life/limb threatening bleeding; BFC Terms of Reference approved; Tocilizumab. Minute from Wound Formulary Group; IV Therapy Group; Lothian Formulary Committee.
<b>FORMULARY UPDATES BROUGHT TO BFC MEETING – 24<sup>TH</sup> FEBRUARY 2021</b>
Sodium zirconium cyclosilicate (Lokelma); Dabigatran; Sarilumab. SMC Decisions update and East Regional Formulary update.
<b>GUIDELINE AND PROTOCOL UPDATES BROUGHT TO BFC MEETING – 24<sup>TH</sup> FEBRUARY 2021</b>
Guanfacine in ADHD SCA; Colchicine. Minute from Anticoagulation Committee; Lothian Formulary Committee.

## 5 BFC – Applications and Decisions

### New Medicine Product/Device Endorsement Categories

<b>A</b>	Approved for general use - hospital and general practice
<b>B</b>	Approved for specialist use only
<b>C</b>	Approved for specialist initiation, with ongoing prescribing in general practice
<b>D</b>	Approved for shared care between hospital and general practice. Shared care protocol to be developed. (Information included here)
<b>E</b>	Not approved (reason given)
<b>F</b>	No decision – further information required (listed here)

NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 8 <sup>TH</sup> APRIL 2020			
NMA	Indication	Speciality	BFC Decision
No applications – meeting cancelled			
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 10 <sup>TH</sup> JUNE 2020			
NMA	Indication	Speciality	BFC Decision
Ustekinumab (Stelera)	Treatment of adult patients with moderately to severe active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies	Gastroenterology	Category B
Fampridine (Fampyra)	For the improvement of walking in patients with multiple sclerosis with walking disability (EDSS expanded disability status scale 4-7)	Neurology	Category B
Guanfacine	For attention deficit hyperactivity disorder (ADHD) in children aged 6 to 18 years	Paediatrics	Category B (third choice in BfJ)
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 19 <sup>TH</sup> AUGUST 2020			
NMA	Indication	Speciality	BFC Decision
Benralizumab (Fasenra)	An add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting $\beta$ -agonists. SMC restriction: patients with blood eosinophils $\geq 150$ cells/microlitre, and either $\geq 4$ prior asthma exacerbations needing systemic corticosteroids in the previous 12 months or treatment with continuous oral corticosteroids over the previous 6 months.	Respiratory	Category B
NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 21 <sup>ST</sup> OCTOBER 2020			
NMA	Indication	Speciality	BFC Decision
Andexanet alfa (Ondexxya)	For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.	Anticoagulation	Category B
Budesonide (Jorveza)	Treatment of eosinophilic oesophagitis (EoE) in adults (older than 18 years of age). SMC restriction: For patients unsuccessfully treated with proton pump inhibitors.	Gastroenterology	Category C
Meropenem /	Treatment of the following infections in		Category B

Vaborbactam (Vaborem)	adults; Complicated urinary tract infection (cUTI) including pyelonephritis; Complicated intra-abdominal infection (cIAI); Hospital-acquired pneumonia (HAP) including ventilator associated pneumonia (VAP).		
Cinacalcet (Mimpara)	Specialist initiation in renal patients with secondary hyperparathyroidism or tertiary hyperparathyroidism, who have very uncontrolled plasma levels of intact parathyroid hormone (greater than 800pg/ml). That are refractory to standard therapy and in whom surgical parathyroidectomy is not suitable.	Dialysis	Category C
Insulin glargine/lixisenatide (Suliqua)	In combination with metformin for the treatment of adults with type 2 diabetes mellitus (T2DM), to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose-lowering medicinal product or with basal insulin.	Endocrinology	Category F – when info received - Category C
Erenumab (Aimovig)	Prophylaxis of migraine in adults who have at least four migraine days per month. SMC restriction: patients with chronic migraine and in whom at least three prior prophylactic treatments have failed.	Neurology	Category B
Semaglutide (Rybelsus)	Treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise - As monotherapy when metformin is considered inappropriate due to intolerance or contraindications; In combination with other medicinal products for the treatment of diabetes. SMC restriction: In addition to other oral anti-diabetic medicines, or as an add-on to basal insulin, as an alternative glucagon-like peptide-1 receptor agonist option	Endocrinology	Category A
<b>NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 16<sup>TH</sup> DECEMBER 2020</b>			
NMA	Indication	Speciality	BFC Decision
Canagliflozin (Invokana)	1st line Sodium-glucose co-transporter 2 (SGLT2) inhibitor for diabetic nephropathy in Type 2 diabetes.	Diabetes	Category A
Cannabidiol oral solution (Epidyolex)	Epilepsy - for seizures associated with Lennox-Gastaut syndrome in conjunction with clobazam or Dravet syndrome in conjunction with clobazam in patients over 2 years of age who are inadequately controlled by other anti-epileptic medicines.	Paediatrics	Category B
FreeStyle Libre2 Sensor	Direct replacement for FreeStyle Libre1 with the same restrictions as at present.	Diabetes	Category C
<b>NEW MEDICINE APPLICATIONS BROUGHT TO BFC MEETING OF 24<sup>TH</sup> FEBRUARY 2021</b>			
NMA	Indication	Speciality	BFC Decision
Remdesivir (Veklury)	Treatment of coronavirus disease 2019 (COVID-19) in adults and adolescents (aged 12 years and older with body weight at least 40kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at	ITU	Category B

	start of treatment.		
Tocilizumab (ROActemra)	Treatment of adult patients admitted to ICU with COVID19 pneumonia	ITU	RED Category
Romosozumab (Evenity)	Treatment of severe osteoporosis in postmenopausal women at high risk of fracture. SMC restriction: to use in patients who have experienced a fragility fracture and are at imminent risk of another fragility fracture (within 24 months).	Rheumatology	Category B

## 6 BFC Meeting Attendees 2020 / 2021

Name	Meeting Dates					
	08.04.2020	10.06.2020	19.08.2020	21.10.2020	16.12.2020	24.02.2021
Mrs Alison Wilson	CANCELLED	✓	✓	✓	✓	✓
Ms Liz Leitch		✓	✓	✓	✓	✓
Mrs Cathryn Park		-	-	-	✓	✓
Mr Keith Maclure		✓	-	✓	✓	✓
Dr Paul Neary		-	✓	✓	✓	✓
Dr Nicola Henderson		✓	✓	✓	✓	✓
Amy Campbell		✓	-	-	-	-
Charlotte Squires		-	✓	-	✓	✓
Michael McDermott		-	✓	✓	✓	-
Fiona Grant		-	-	-	✓	-
Kate Warner (Minute)		✓	✓	✓	✓	✓
Guests						
Dr Jeremy Fellick		✓				
Adrian Mackenzie			✓			
Debra Cairns			✓			
Cheryl Lugton				✓		
Fiona Grant				✓		
Cheryl MacNeil					✓	
Nicola Robertson					✓	
Deborah Watson					✓	
Gillian Donaldson						✓

### Declarations of Interest

No declarations of interest during 2020/21 meetings.